• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5074679)   Today's Articles (206)
For: Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol 2024;35:77-90. [PMID: 37879444 DOI: 10.1016/j.annonc.2023.10.117] [Citation(s) in RCA: 131] [Impact Index Per Article: 131.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 10/11/2023] [Accepted: 10/12/2023] [Indexed: 10/27/2023]  Open
Number Cited by Other Article(s)
51
Zhang J, Li W. Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. BMC Pulm Med 2025;25:63. [PMID: 39915804 PMCID: PMC11800505 DOI: 10.1186/s12890-025-03509-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2024] [Accepted: 01/20/2025] [Indexed: 02/11/2025]  Open
52
Otsuka S, Nagano Y, Shioya M, Ohkawa H, Kato T. Salvage Surgery for Epidermal Growth Factor Receptor-Mutant Lung Cancer With Osimertinib Resistance: A Case Report. Cureus 2025;17:e78461. [PMID: 40051929 PMCID: PMC11883140 DOI: 10.7759/cureus.78461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/31/2025] [Indexed: 03/09/2025]  Open
53
Zhou F, Guo H, Xia Y, Le X, Tan DSW, Ramalingam SS, Zhou C. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol 2025;22:95-116. [PMID: 39614090 DOI: 10.1038/s41571-024-00971-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/15/2024] [Indexed: 12/01/2024]
54
Liao YY, Tsai CL, Huang HP. Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics. Cancers (Basel) 2025;17:459. [PMID: 39941826 PMCID: PMC11815769 DOI: 10.3390/cancers17030459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2024] [Revised: 01/24/2025] [Accepted: 01/27/2025] [Indexed: 02/16/2025]  Open
55
Mina SA, Shanshal M, Leventakos K, Parikh K. Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC). Cancers (Basel) 2025;17:353. [PMID: 39941723 PMCID: PMC11816067 DOI: 10.3390/cancers17030353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2024] [Revised: 01/13/2025] [Accepted: 01/18/2025] [Indexed: 02/16/2025]  Open
56
Liao Z, Luo C, Huang Y, Jiang Z, Wei H, Wang Y. Evaluation of the safety profile of amivantamab based on real-world evidence: a call to vigilance. Expert Opin Drug Saf 2025:1-10. [PMID: 39829078 DOI: 10.1080/14740338.2025.2456167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2024] [Accepted: 11/18/2024] [Indexed: 01/22/2025]
57
Moik F, Absenger G, Wurm R, Hochmair MJ, Ay C. Prevention and Treatment of Venous Thromboembolism Associated with Amivantamab-Based Therapies in Patients with Lung Cancer-Provisional Clinical Opinion Based on Existing Clinical Practice Guidelines. Cancers (Basel) 2025;17:259. [PMID: 39858040 PMCID: PMC11763553 DOI: 10.3390/cancers17020259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2024] [Revised: 01/09/2025] [Accepted: 01/11/2025] [Indexed: 01/27/2025]  Open
58
Korn EL, Allegra CJ, Freidlin B. Phase III Evaluation of Treatment Combinations in Three-Arm Trials. J Clin Oncol 2025;43:226-233. [PMID: 39467219 DOI: 10.1200/jco-24-01476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2024] [Revised: 08/13/2024] [Accepted: 09/20/2024] [Indexed: 10/30/2024]  Open
59
Torresan S, Bortolot M, De Carlo E, Bertoli E, Stanzione B, Del Conte A, Spina M, Bearz A. Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer. Int J Mol Sci 2025;26:554. [PMID: 39859270 PMCID: PMC11765312 DOI: 10.3390/ijms26020554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2024] [Revised: 12/30/2024] [Accepted: 01/08/2025] [Indexed: 01/27/2025]  Open
60
Wang M, Xu Y, Huang WT, Su WC, Gao B, Lee CK, Fang J, Zhu X, Yang Z, Jänne PA, Yang JCH. Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations. Lung Cancer 2025;199:108053. [PMID: 39647463 DOI: 10.1016/j.lungcan.2024.108053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2024] [Revised: 11/21/2024] [Accepted: 12/01/2024] [Indexed: 12/10/2024]
61
Borghaei H, Mok T. Leptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met. J Thorac Oncol 2025;20:17-19. [PMID: 39794099 DOI: 10.1016/j.jtho.2024.10.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2024] [Accepted: 10/29/2024] [Indexed: 01/13/2025]
62
Wu S, Ho C, Yang JC, Yu S, Lin Y, Lin S, Liao B, Yang C, Lin Y, Yu C, Chuang Y, Liao W, Yap KY, Kou WS, Shih J. Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. Clin Transl Med 2025;15:e70149. [PMID: 39715697 PMCID: PMC11666332 DOI: 10.1002/ctm2.70149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2024] [Revised: 12/05/2024] [Accepted: 12/10/2024] [Indexed: 12/25/2024]  Open
63
Gao M, Zhang X, Yan H, Zhao Y, Yuan F, Sun D, Yang X, Ju Y, Wang L, Tao H, Tian L, Zhao C, Ma J, Hu Y, Liu Z. Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial. Ther Adv Med Oncol 2025;17:17588359241311058. [PMID: 39759826 PMCID: PMC11694305 DOI: 10.1177/17588359241311058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2024] [Accepted: 12/16/2024] [Indexed: 01/07/2025]  Open
64
Robinson ND, Canavan ME, Zhan PL, Udelsman BV, Pathak R, Boffa DJ, Goldberg SB. Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer After Progression on Osimertinib. Clin Lung Cancer 2025;26:9-17.e3. [PMID: 39462746 DOI: 10.1016/j.cllc.2024.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2024] [Revised: 08/14/2024] [Accepted: 09/19/2024] [Indexed: 10/29/2024]
65
Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. Lung Cancer 2025;199:108040. [PMID: 39615411 PMCID: PMC11787869 DOI: 10.1016/j.lungcan.2024.108040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2024] [Revised: 10/10/2024] [Accepted: 11/23/2024] [Indexed: 01/30/2025]
66
Kumar MS, Deshmukh S, Bhanushali C, Boumber Y, Riess J, Naqash AR, Subbiah V, Desai A. Biomarker Landscape of Antibody Drug Conjugates (ADCs) and Bispecific Antibodies in Clinical Trials for Lung Cancer. Clin Lung Cancer 2025;26:e5-e10. [PMID: 39592292 DOI: 10.1016/j.cllc.2024.10.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2024] [Revised: 10/14/2024] [Accepted: 10/16/2024] [Indexed: 11/28/2024]
67
Mehlman C, Swalduz A, Monnet I, Morin C, Wislez M, Guisier F, Curcio H, Du Rusquec P, Cortot AB, Gounant V, Abbar B, Duchemann B, Giroux-Leprieur E, Pierret T, Quilot FM, Cadranel J, Fallet V. COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer. Oncologist 2024:oyae312. [PMID: 39724403 DOI: 10.1093/oncolo/oyae312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2024] [Accepted: 10/17/2024] [Indexed: 12/28/2024]  Open
68
Bazhenova L, Ismaila N, Abu Rous F, Alluri K, Freeman-Daily J, Halmos B, Malhotra N, Marrone KA, Puri S, Qin A, Leighl NB. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2. J Clin Oncol 2024;42:e72-e86. [PMID: 39531596 DOI: 10.1200/jco-24-02133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2024] [Accepted: 10/04/2024] [Indexed: 11/16/2024]  Open
69
Liu DW, Zhou XA, Wu XY, Wang YX, Fan JT, Li ZL. Mindfulness-based stress reduction training and supplemented Jinshui Liujun decoction promote recovery in patients with non-small cell lung cancer. World J Psychiatry 2024;14:1876-1885. [PMID: 39704353 PMCID: PMC11622032 DOI: 10.5498/wjp.v14.i12.1876] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2024] [Revised: 09/17/2024] [Accepted: 09/27/2024] [Indexed: 11/27/2024]  Open
70
Abdallah M, Voland R, Decamp M, Flickinger J, Pacioles T, Jamil M, Silbermins D, Shenouda M, Valsecchi M, Bir A, Shweihat Y, Bastidas J, Chowdhury N, Kachynski Y, Eldib H, Wright T, Mahdi A, Al-Nusair J, Nwanwene K, Varlotto J. Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer. Cancers (Basel) 2024;16:4207. [PMID: 39766108 PMCID: PMC11674749 DOI: 10.3390/cancers16244207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2024] [Revised: 11/23/2024] [Accepted: 12/10/2024] [Indexed: 01/11/2025]  Open
71
Sun K, Wang P. A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review. Front Oncol 2024;14:1467722. [PMID: 39743996 PMCID: PMC11688600 DOI: 10.3389/fonc.2024.1467722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2024] [Accepted: 12/03/2024] [Indexed: 01/04/2025]  Open
72
Li Y, Long Y, Ge X, Zhang P, Li T, Wu L, Fan H, Du Z, Liu Q, Hu Y. Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del. Vaccines (Basel) 2024;12:1412. [PMID: 39772073 PMCID: PMC11680254 DOI: 10.3390/vaccines12121412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2024] [Revised: 12/06/2024] [Accepted: 12/09/2024] [Indexed: 01/11/2025]  Open
73
Li MSC, Chan ALS, Mok KKS, Chan LL, Mok TSK. Next-generation immunotherapy: igniting new hope for lung cancer. Ther Adv Med Oncol 2024;16:17588359241302021. [PMID: 39649017 PMCID: PMC11624561 DOI: 10.1177/17588359241302021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2024] [Accepted: 11/06/2024] [Indexed: 12/10/2024]  Open
74
van der Wel JWT, Boelens MC, Jebbink M, Smulders SA, Maas KW, Luitse MJA, Compter A, Boltjes RPB, Sol N, Monkhorst K, van den Broek D, Smit EF, de Langen AJ, Brandsma D. Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol 2024;26:2316-2327. [PMID: 39110039 PMCID: PMC11630515 DOI: 10.1093/neuonc/noae138] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2024]  Open
75
Podder V, Ranjan T, Gowda M, Camacho AM, Ahluwalia MS. Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review. Curr Neurol Neurosci Rep 2024;25:6. [PMID: 39625633 DOI: 10.1007/s11910-024-01388-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/19/2024] [Indexed: 12/17/2024]
76
Webendörfer M, Heinzen S, Sibbert C, Leßmann ME, Kropf-Sanchen C, Thomas M, Tufman A, Bleckmann A, Wiesweg M, Griesinger F, Reitnauer L, Overbeck TR. Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024: Targeted Therapies in Non-Small Cell Lung Cancer. Oncol Res Treat 2024;48:142-147. [PMID: 39626649 DOI: 10.1159/000542957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2024] [Accepted: 11/25/2024] [Indexed: 03/05/2025]
77
Ketpueak T, Tan DSW, Popat S. Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: End of the Road or the First Chapter? J Clin Oncol 2024;42:4003-4007. [PMID: 39186708 DOI: 10.1200/jco.24.00829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2024] [Revised: 05/04/2024] [Accepted: 05/15/2024] [Indexed: 08/28/2024]  Open
78
Meyer ML, Peters S, Mok TS, Lam S, Yang PC, Aggarwal C, Brahmer J, Dziadziuszko R, Felip E, Ferris A, Forde PM, Gray J, Gros L, Halmos B, Herbst R, Jänne PA, Johnson BE, Kelly K, Leighl NB, Liu S, Lowy I, Marron TU, Paz-Ares L, Rizvi N, Rudin CM, Shum E, Stahel R, Trunova N, Bunn PA, Hirsch FR. Lung cancer research and treatment: global perspectives and strategic calls to action. Ann Oncol 2024;35:1088-1104. [PMID: 39413875 DOI: 10.1016/j.annonc.2024.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2024] [Revised: 10/02/2024] [Accepted: 10/04/2024] [Indexed: 10/18/2024]  Open
79
Lee SH, Menis J, Kim TM, Kim HR, Zhou C, Kurniawati SA, Prabhash K, Hayashi H, Lee DDW, Imasa MS, Teh YL, Yang JCH, Reungwetwattana T, Sriuranpong V, Wu CE, Ang Y, Sabando M, Thiagarajan M, Mizugaki H, Noronha V, Yulianti M, Zhang L, Smyth E, Yoshino T, Park JO, Pentheroudakis G, Park S, Peters S, Ahn JB, Popat S. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer. ESMO Open 2024;9:103996. [PMID: 39615406 DOI: 10.1016/j.esmoop.2024.103996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2024] [Revised: 10/14/2024] [Accepted: 10/28/2024] [Indexed: 12/24/2024]  Open
80
Watson AS, Krause HB, Elliott A, Farrell A, Liu SV, Ma PC, VanderWalde A, Sledge GW, Spetzler D, Schenk EL, Camidge DR. Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer. Clin Lung Cancer 2024;25:712-722.e1. [PMID: 39384504 DOI: 10.1016/j.cllc.2024.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2024] [Revised: 09/05/2024] [Accepted: 09/07/2024] [Indexed: 10/11/2024]
81
Bestvina CM, Waters D, Morrison L, Emond B, Lafeuille MH, Hilts A, Mujwara D, Lefebvre P, He A, Vanderpoel J. Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non-small cell lung cancer. J Manag Care Spec Pharm 2024;30:1467-1478. [PMID: 39259000 DOI: 10.18553/jmcp.2024.24137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/12/2024]
82
Liu A, Wang X, Wang L, Zhuang H, Xiong L, Gan X, Wang Q, Tao G. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis. BMC Cancer 2024;24:1390. [PMID: 39533233 PMCID: PMC11555867 DOI: 10.1186/s12885-024-13168-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2024] [Accepted: 11/07/2024] [Indexed: 11/16/2024]  Open
83
Hockemeyer KG, Rusthoven CG, Pike LRG. Advances in the Management of Lung Cancer Brain Metastases. Cancers (Basel) 2024;16:3780. [PMID: 39594735 PMCID: PMC11593022 DOI: 10.3390/cancers16223780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2024] [Revised: 11/01/2024] [Accepted: 11/04/2024] [Indexed: 11/28/2024]  Open
84
Jiang Z, Gu Z, Yu X, Cheng T, Liu B. Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Front Oncol 2024;14:1447678. [PMID: 39582541 PMCID: PMC11581962 DOI: 10.3389/fonc.2024.1447678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Accepted: 09/25/2024] [Indexed: 11/26/2024]  Open
85
Parikh K, Dimou A, Leventakos K, Mansfield AS, Shanshal M, Wan Y, Lin HM, Vincent S, Elliott J, Bonta IR. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database. J Thorac Oncol 2024;19:1539-1549. [PMID: 39019326 DOI: 10.1016/j.jtho.2024.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Revised: 06/18/2024] [Accepted: 07/11/2024] [Indexed: 07/19/2024]
86
Chan KL, Faiz SA, Altan M, Sheshadri A. Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies. JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY 2024;7:272-282. [PMID: 39524467 PMCID: PMC11541925 DOI: 10.36401/jipo-24-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Revised: 06/11/2024] [Accepted: 07/07/2024] [Indexed: 11/16/2024]
87
Ardeshir-Larijani F, Ramalingam SS. The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC. Nat Rev Clin Oncol 2024;21:767-768. [PMID: 39160242 DOI: 10.1038/s41571-024-00938-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/21/2024]
88
Watanabe K, Hosomi Y, Naoki K, Nakahara Y, Tsukita Y, Matsumoto H, Yoh K, Fujisaka Y, Takahashi S, Takata S, Usui K, Kishi K, Naka G, Tamano S, Uemura K, Kunitoh H. The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study). JTO Clin Res Rep 2024;5:100720. [PMID: 39416709 PMCID: PMC11480219 DOI: 10.1016/j.jtocrr.2024.100720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2024] [Revised: 08/03/2024] [Accepted: 08/17/2024] [Indexed: 10/19/2024]  Open
89
Corvaja C, Passaro A, Attili I, Aliaga PT, Spitaleri G, Signore ED, de Marinis F. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development. Cancer Treat Rev 2024;130:102824. [PMID: 39366135 DOI: 10.1016/j.ctrv.2024.102824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2024] [Revised: 08/31/2024] [Accepted: 09/02/2024] [Indexed: 10/06/2024]
90
Malhotra J, Kim ES. How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer. JCO Oncol Pract 2024;20:1471-1480. [PMID: 39531842 DOI: 10.1200/op.24.00230] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2024] [Revised: 05/08/2024] [Accepted: 06/26/2024] [Indexed: 11/16/2024]  Open
91
Wang K, Leyba A, Hsu R. Addressing the unmet need in NSCLC progression with advances in second-line therapeutics. EXPLORATION OF TARGETED ANTI-TUMOR THERAPY 2024;5:1297-1320. [PMID: 39759220 PMCID: PMC11700623 DOI: 10.37349/etat.2024.00277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2024] [Accepted: 10/16/2024] [Indexed: 01/07/2025]  Open
92
Sampat PJ, Cortese A, Goodman A, Ghelani GH, Mix MD, Graziano S, Basnet A. Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research. Front Oncol 2024;14:1411432. [PMID: 39534096 PMCID: PMC11554526 DOI: 10.3389/fonc.2024.1411432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2024] [Accepted: 10/04/2024] [Indexed: 11/16/2024]  Open
93
Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JCH, Thomas M, Nguyen D, Ou SHI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med 2024;391:1486-1498. [PMID: 38924756 DOI: 10.1056/nejmoa2403614] [Citation(s) in RCA: 90] [Impact Index Per Article: 90.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/28/2024]
94
Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massutí B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Şendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol 2024;42:3593-3605. [PMID: 38857463 PMCID: PMC11469630 DOI: 10.1200/jco.24.01001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2024] [Revised: 05/29/2024] [Accepted: 06/04/2024] [Indexed: 06/12/2024]  Open
95
Wang K, Hsu R. Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions. Antibodies (Basel) 2024;13:88. [PMID: 39449330 PMCID: PMC11503282 DOI: 10.3390/antib13040088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2024] [Revised: 10/12/2024] [Accepted: 10/17/2024] [Indexed: 10/26/2024]  Open
96
Shi M, Chen P, Cui B, Yao Y, Wang J, Zhou T, Wang L. Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study. Signal Transduct Target Ther 2024;9:283. [PMID: 39389963 PMCID: PMC11467201 DOI: 10.1038/s41392-024-01982-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2024] [Revised: 09/06/2024] [Accepted: 09/16/2024] [Indexed: 10/12/2024]  Open
97
Hong MH, Choi YJ, Ahn HK, Lim SM, Keam B, Kim DW, Kim TM, Youk J, Kim YJ, Hwang S, Kim S, Kim JW, Kim HR, Kang JH. Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial. JAMA Oncol 2024;10:1342-1351. [PMID: 39145962 PMCID: PMC11327907 DOI: 10.1001/jamaoncol.2024.2640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Accepted: 04/01/2024] [Indexed: 08/16/2024]
98
Cheng H. The Role of Lazertinib in Patients With EGFR-Variant Non-Small Cell Lung Cancer. JAMA Oncol 2024;10:1352-1353. [PMID: 39145952 DOI: 10.1001/jamaoncol.2024.2607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/16/2024]
99
Okuno T, Isobe T, Tsubata Y. Current pharmacologic treatment of brain metastasis in non-small cell lung cancer. Clin Exp Metastasis 2024;41:549-565. [PMID: 38466521 PMCID: PMC11499348 DOI: 10.1007/s10585-024-10276-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Accepted: 01/28/2024] [Indexed: 03/13/2024]
100
Makarem M, Jänne PA. Top advances of the year: Targeted therapy for lung cancer. Cancer 2024;130:3239-3250. [PMID: 39031586 DOI: 10.1002/cncr.35423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 04/15/2024] [Accepted: 05/13/2024] [Indexed: 07/22/2024]
PrevPage 2 of 4 1234Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA